---

---

entities : Bristol-myers squibb company   

save search

---

Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company
Published: 2022-06-03 (Crawled : 12:00) - biospace.com/
BMY | $49.2 0.12% 2.9M |

Health Technology

| -34.89% | O: -1.4% H: 0.0% C: 0.0%
TPTX | $76.01 -0.03% |

Health Technology

| 126.63% | O: 120.04% H: 0.0% C: 0.0%

---

PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion
Published: 2023-12-22 (Crawled : 20:00) - biospace.com/
PTCHF | $2.61 4.1K |

n/a

| 39.27% | O: 29.67% H: 0.0% C: -5.76%
BMY | $49.2 0.12% 2.9M |

Health Technology

| -4.14% | O: -0.78% H: 5.15% C: 2.81%
KRTX | $329.83 0.0% 1.9M |

Health Technology

| 53.27% | O: 47.74% H: 0.0% C: 0.0%
therapeutics acquired

---

Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus’ Anti-TIGIT Bispecific Antibody Program
Published: 2021-05-18 (Crawled : 12:00) - biospace.com/
BMY | $49.2 0.12% 2.9M |

Health Technology

| -24.93% | O: -0.06% H: 0.58% C: 0.28%
AGEN A | $6.93 20.1% 710K |

Health Technology

| 76.99% | O: 29.45% H: 6.64% C: -6.87%
antibody license

---

Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus’ Anti-TIGIT Bispecific Antibody ProgramAgenus to receive a $200 million upfront payment and up to $1.36 billion in milestone payments
Published: 2021-05-18 (Crawled : 12:15) - biospace.com/
BMY | $49.2 0.12% 2.9M |

Health Technology

| -24.93% | O: -0.06% H: 0.58% C: 0.28%
AGEN A | $6.93 20.1% 710K |

Health Technology

| 76.99% | O: 29.45% H: 6.64% C: -6.87%
antibody license milestone

---

Avidity Biosciences Announces Expansion of Cardiovascular Collaboration with Bristol Myers Squibb for up to Five Targets Utilizing Avidity's Proprietary AOC™ Platform Technology
Published: 2023-11-28 (Crawled : 20:00) - biospace.com/
BMY | $49.2 0.12% 2.9M |

Health Technology

| 0.24% | O: 0.06% H: 0.55% C: -0.27%
RNA | News M | $25.4 5.13% 430K |

Health Technology

| 292.21% | O: 25.32% H: 3.63% C: -8.29%
expansion collaboration technology cardiovascular platform

---

Gritstone Announces Updated Overall Survival Results in Advanced Colorectal Cancer Patients from Phase 1/2 Study of GRANITE and Trial in Progress Poster at ASCO
Published: 2022-05-31 (Crawled : 17:00) - biospace.com/
BMY | $49.2 0.12% 2.9M |

Health Technology

| -35.46% | O: -1.39% H: 1.2% C: 0.49%
GRTS | $0.7411 -0.59% 1.6M |

Health Technology

| -59.46% | O: 7.03% H: 18.69% C: 2.02%
trial asco results cancer phase 1

---

SELLAS Announces Publication of Positive GPS Clinical Data in Ovarian Cancer in Peer Reviewed Journal
Published: 2023-03-07 (Crawled : 14:00) - globenewswire.com
BMY | $49.2 0.12% 2.9M |

Health Technology

| -28.68% | O: 0.41% H: 0.04% C: -1.71%
SLS | $1.635 6.17% 1.1M |

Health Technology

| -1.91% | O: 3.82% H: 1.23% C: -4.91%
positive cancer publication ovarian cancer

---

Idiopathic Pulmonary Fibrosis Market to Reach $6.16 Bn, Globally, by 2030 at 7.0% CAGR: Allied Market Research
Published: 2022-02-07 (Crawled : 13:30) - prnewswire.com
AZNCF | News | $138.73 3.7K |

Health Technology

| 25.51% | O: 2.69% H: 0.5% C: -1.76%
BMY | $49.2 0.12% 2.9M |

Health Technology

| -22.06% | O: 3.7% H: 1.64% C: 1.24%
GLPG | News | $29.695 2.15% 69K |

Health Technology

| -55.31% | O: 2.54% H: 1.58% C: 0.1%
FGEN | $1.15 0.88% 700K |

Health Technology

| -92.23% | O: -1.09% H: 9.3% C: 8.82%
BIIB | $194.31 0.1% 470K |

Health Technology

| -9.82% | O: 2.54% H: 0.0% C: 0.0%
AZN | News | $70.87 1.06% 3M |

Health Technology

| 24.63% | O: -0.14% H: 1.01% C: 0.87%
fibrosis research

---

Lymphoma Treatment Global Market to Reach $18.5 Billion by 2027 at a CAGR of 8.89%
Published: 2022-11-10 (Crawled : 13:00) - prnewswire.com
TAK | News | $13.4 0.3% 790K |

Health Technology

| 1.06% | O: 2.34% H: 2.51% C: 2.29%
JNJ | News | $150.09 0.65% 3.9M |

Health Technology

| -14.37% | O: 0.18% H: 0.0% C: 0.0%
LLY | News | $741.37 1.37% 800K |

Health Technology

| 101.32% | O: 1.09% H: 0.48% C: 0.4%
BMY | $49.2 0.12% 2.9M |

Health Technology

| -38.41% | O: 1.22% H: 0.01% C: -1.7%
ABT | News | $108.01 0.88% 1.2M |

Health Technology

| 7.65% | O: 3.59% H: 1.37% C: 1.16%
treatment global market

---

Global Hairy Cell Leukemia Market Analysis & Forecast 2024-2034
Published: 2024-02-02 (Crawled : 03:00) - prnewswire.com
NVS | News | $97.31 2.3% 2.3M |

Health Technology

| -10.03% | O: -0.5% H: 0.26% C: -1.03%
JNJ | News | $150.09 0.65% 3.9M |

Health Technology

| -5.66% | O: -0.15% H: 0.0% C: 0.0%
BMY | $49.2 0.12% 2.9M |

Health Technology

| 0.97% | O: 1.23% H: 1.5% C: -1.14%
ABBV | News | $170.19 1.37% 1.6M |

Health Technology

| 2.62% | O: 3.59% H: 0.0% C: 0.0%
AMGN | News | $273.38 0.54% 790K |

Health Technology

| -16.22% | O: -0.28% H: 0.66% C: -0.14%
cell global leukemia market

---

Gritstone Announces Dosing of First Solid Tumor Patient with Optimized SLATE “Off-the-Shelf” Mutant KRAS-directed Neoantigen Immunotherapy in Phase 2 Clinical Trial
Published: 2021-09-17 (Crawled : 12:00) - biospace.com/
BMY | $49.2 0.12% 2.9M |

Health Technology

| -19.75% | O: -1.14% H: 0.0% C: 0.0%
GRTS | $0.7411 -0.59% 1.6M |

Health Technology

| -94.46% | O: 3.4% H: 0.0% C: 0.0%
phase 2 immunotherapy therapy trial solid tumors

---

Gritstone Announces Positive Clinical Data with GRANITE (Individualized Neoantigen Immunotherapy Program) during ESMO 2021 and Launch of Randomized Clinical Trial Program in Colorectal Cancer with Registrational Intent
Published: 2021-09-17 (Crawled : 12:00) - globenewswire.com
BMY | $49.2 0.12% 2.9M |

Health Technology

| -19.75% | O: -1.14% H: 0.0% C: 0.0%
GRTS | $0.7411 -0.59% 1.6M |

Health Technology

| -94.46% | O: 3.4% H: 0.0% C: 0.0%
immunotherapy positive therapy cancer colorectal cancer trial program

---

Frost & Sullivan Institute lauds Global Companies with Prestigious Enlightened Growth Leadership Awards
Published: 2022-08-04 (Crawled : 13:20) - prnewswire.com
ATGFF | $21.6023 20K |

n/a

| -1.58% | O: -0.47% H: 1.17% C: 1.17%
CNXC | News P | $56.39 2.16% 160K |

Information

| -59.54% | O: -0.26% H: 0.77% C: 0.06%
CRK | $9.85 1.23% 1.2M |

Energy Minerals

| -41.67% | O: -0.3% H: 1.53% C: -7.46%
CNC | $76.3 0.95% 590K |

Health Services

| -18.56% | O: 0.12% H: 0.54% C: 0.06%
BAM | $39.55 1.28% 590K |

Finance

| -21.48% | O: 0.26% H: 0.82% C: 0.82%
BMY | $49.2 0.12% 2.9M |

Health Technology

| -32.68% | O: -0.27% H: 0.22% C: -0.92%
AVTR | $25.755 5.51% 2.6M |

Process Industries

| -14.86% | O: 0.17% H: 0.17% C: -0.59%
DXCM | $134.4 2.19% 930K |

Health Technology

| 45.5% | O: -0.17% H: 0.6% C: -0.78%
BLDR 4 | $186.075 4.41% 860K |

Producer Manufacturing

| 158.24% | O: -0.74% H: 3.87% C: 3.37%
AMZN S | $178.87 0.93% 19M |

Retail Trade

| 30.13% | O: 3.23% H: 0.0% C: 0.0%
ALGN | $309.7 2.95% 210K |

Health Technology

| 5.1% | O: 0.15% H: 3.36% C: 2.48%
AEIS F | $94.0 3.26% 59K |

Electronic Technology

| -1.98% | O: 2.29% H: 3.16% C: -0.94%
awards global companies growth

---

Bolt Biotherapeutics to Present Interim Clinical Data on BDC-1001 Phase 1/2 Clinical Trial at ESMO Immuno-Oncology Congress 2021
Published: 2021-12-02 (Crawled : 11:00) - globenewswire.com
BOLT | $1.11 24K |

| -88.27% | O: 3.22% H: 8.6% C: 6.35%
BMY | $49.2 0.12% 2.9M |

Health Technology

| -8.85% | O: 2.17% H: 0.0% C: 0.0%
trial therapeutics phase 1 iot

---

Rising R&D Investment and Government Support Fuel Expansion of Global Duchenne Muscular Dystrophy Drugs Market
Published: 2023-10-24 (Crawled : 23:00) - prnewswire.com
PFE | News A | $26.24 -0.08% 11M |

Health Technology

| -13.7% | O: 0.1% H: 1.77% C: 0.89%
LLY | News | $741.37 1.37% 800K |

Health Technology

| 25.88% | O: 2.75% H: 0.46% C: -1.76%
BMY | $49.2 0.12% 2.9M |

Health Technology

| -12.44% | O: -0.18% H: 1.34% C: 1.05%
PTCT | News S | $25.72 -0.96% 140K |

Health Technology

| 11.84% | O: -1.34% H: 2.23% C: 1.62%
LXRX | $1.685 -1.46% 1.2M |

Health Technology

| 43.7% | O: -1.68% H: 0.85% C: -2.99%
expansion global duchenne market

---

Transdermal Drug Delivery Market is Growing at a CAGR of 9.8% during the Study Period from 2021 to 2026, Asserts DelveInsight
Published: 2021-12-14 (Crawled : 17:00) - prnewswire.com
TRUMF | $16.488 1.7K |

Health Technology

| -61.06% | O: -1.42% H: 0.02% C: 0.02%
SNYNF | News | $92.7 600K |

Health Technology

| -5.03% | O: -3.62% H: 0.0% C: -0.56%
AZNCF | News | $138.73 3.7K |

Health Technology

| 29.32% | O: -1.44% H: 5.82% C: 1.91%
TRUMY | $16.94 52K |

Manufacturing

| -59.15% | O: -1.37% H: 0.68% C: 0.37%
NVO | News | $128.31 2.44% 2.2M |

Health Technology

| 8.55% | O: -1.8% H: 0.08% C: -0.43%
MDT | $80.95 0.47% 1.7M |

Health Technology

| -28.38% | O: -0.2% H: 0.66% C: -0.52%
JNJ | News | $150.09 0.65% 3.9M |

Health Technology

| -9.67% | O: 1.9% H: 0.0% C: 0.0%
LLY | News | $741.37 1.37% 800K |

Health Technology

| 197.63% | O: 0.82% H: 0.92% C: 0.66%
BMY | $49.2 0.12% 2.9M |

Health Technology

| -14.17% | O: 2.71% H: 2.77% C: 1.21%
BDX | $235.075 0.51% 280K |

Health Technology

| -7.49% | O: -0.3% H: 0.1% C: -1.63%
SNY | News | $47.85 1.49% 920K |

Health Technology

| -4.78% | O: -0.51% H: 0.0% C: 0.0%
PODD | $167.055 1.6% 190K |

Health Technology

| -37.86% | O: -0.82% H: 0.38% C: -2.71%
ENDP | News | $0.2926 -9.6% |

Health Technology

| -93.51% | O: -5.76% H: 7.53% C: 0.47%
AZN | News | $70.87 1.06% 3M |

Health Technology

| 29.15% | O: 0.33% H: 0.0% C: 0.0%
ATRS | $5.59 0.0% |

Health Technology

| 74.14% | O: -0.31% H: 0.7% C: -0.63%
drug liver growing drug delivery

---

AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS
Published: 2023-10-31 (Crawled : 11:00) - prnewswire.com
SNYNF | News | $92.7 600K |

Health Technology

| 4.76% | O: 4.66% H: 0.0% C: -3.51%
BMY | $49.2 0.12% 2.9M |

Health Technology

| -4.12% | O: 0.25% H: 0.54% C: 0.29%
XNCR | $18.45 1.32% 190K |

Health Technology

| 5.69% | O: -0.41% H: 2.1% C: 1.11%
SNY | News | $47.85 1.49% 920K |

Health Technology

| 4.22% | O: 2.61% H: 0.0% C: 0.0%
REGN | News | $908.42 0.92% 130K |

Health Technology

| 15.75% | O: -0.33% H: 0.92% C: 0.61%
BGNE | $138.615 5.86% 110K |

Health Technology

| -29.83% | O: 0.14% H: 0.68% C: -0.32%
AMGN | News | $273.38 0.54% 790K |

Health Technology

| 3.31% | O: -2.77% H: 0.6% C: -0.07%
financial results

---

Checkmate Pharmaceuticals Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate CMP-001 in Combination with Nivolumab
Published: 2020-12-08 (Crawled : 12:02) - globenewswire.com
BMY | $49.2 0.12% 2.9M |

Health Technology

| -19.71% | O: -0.05% H: 1.0% C: -0.08%
CMPI | $10.5 0.0% |

Health Technology

| -25.32% | O: 2.49% H: 10.34% C: 10.34%
collaboration nivolumab

---

Bristol Myers Squibb Reports First Quarter Financial Results for 2022
Published: 2022-04-29 (Crawled : 12:00) - biospace.com/
BMY | $49.2 0.12% 2.9M |

Health Technology

| -35.8% | O: -3.61% H: 3.02% C: 2.02%
NKTR | News | $1.4 2.94% 600K |

Health Technology

| -66.99% | O: 2.43% H: 2.84% C: -2.13%

---

Bolt Biotherapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
Published: 2022-08-10 (Crawled : 23:00) - biospace.com/
GNMSF | News | $289.67 5.3K |

Health Technology

| -17.24% | O: -0.39% H: 5.07% C: -0.05%
BOLT | $1.11 24K |

| -51.32% | O: 3.07% H: 8.51% C: 7.23%
BMY | $49.2 0.12% 2.9M |

Health Technology

| -34.45% | O: 0.32% H: 0.16% C: -0.45%
GMAB | News | $28.885 -0.29% 190K |

Health Technology

| -17.53% | O: 2.33% H: 0.64% C: -0.72%
update results

---

Gainers vs Losers

87%

13%

Top 10 Gainers

MTTR | News M | $4.64 166.67% 18M |

AGBA | $2.61 108.8% 41M |

Finance

CZOO | $9.32 86.77% 18M |

EDBL | News | $6.7 78.19% 1.7M |

OPRT | News | $3.37 49.78% 8.9M |

Finance

MTC | $2.14 37.18% 4.9M |

Technology Services

VNRX | $0.8 33.33% 2.9M |

Health Technology

MLEC | $1.79 27.86% 2.6M |

n/a

PALI | $6.29 27.59% 22M |

Manufacturing

MCRB | $0.7902 26.51% 6.9M |

Health Technology

---

Your saved searches

---